Anti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model

Qian Xiao; Xiaolei Su

doi:10.21769/BioProtoc.4655

Anti-tumor Efficacy of CD19 CAR-T in a Raji B Cell Xenografted Mouse Model

Bio Protoc. 2023 Apr 20;13(8):e4655. doi: 10.21769/BioProtoc.4655.

Authors

Qian Xiao^{1

2

3}, Xiaolei Su^{1

4}

Affiliations

¹ Department of Cell Biology, Yale School of Medicine, New Haven, CT, 06520, USA.
² Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08903, USA.
³ Department of Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, 08854, USA.
⁴ Yale Cancer Center, Yale University, New Haven, CT, 06520, USA.

Abstract

Chimeric antigen receptor (CAR)-T therapy launched a new era for cancer treatments, displaying outstanding effectiveness in relapsed or refractory B-cell malignancies. Demonstrating the tumor-killing ability of CAR-Ts in mouse xenograft models serves as a golden criterium in preclinical research. Here, we describe a detailed method for evaluating CAR-T's function in immune-deficient mice bearing Raji B cell-induced tumors. It includes generating CD19 CAR-T cells from healthy donors, injecting tumor cells and CAR-T cells into mice, and monitoring tumor growth and CAR-T state. This protocol provides a practical guide to evaluate CAR-T's function in vivo within eight weeks. Graphical abstract.

Keywords: CD19 CAR-T; Chimeric antigen receptor; In vivo tumor killing assay; Raji B cell; Xenografted tumor model.

Grants and funding

R35 GM138299/GM/NIGMS NIH HHS/United States